SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SpaceX engineers reusable launch vehicles and the Starlink satellite constellation for global broadband. Their focus on rapid reusability and vertical integration drives down launch costs and accelerates space access.

SpaceX PreStocks

Investors are actively debating the legitimacy of a tokenized crypto asset claiming to represent SpaceX, with many warning it is a scam while others speculate on its connection to the company's long-rumored IPO. The community conversation is dominated by intense skepticism regarding unauthorized tokens, contrasted with broader market excitement surrounding SpaceX's expected public debut and its potential impact on space-sector stocks.

Uranium Energy Corp. engages in the provision of uranium and titanium mining and related activities, including exploration, pre-extraction, extraction, and processing of uranium concentrates, and titanium minerals. It operates through the following geographical segments: Wyoming, Texas, Saskatchewan, and Others. The company was founded by Alan P. Lindsay and Amir Adnani on May 16, 2003 and is headquartered in Corpus Christi, TX.

Uranium Energy Corp

Uranium Energy Corp is trending as investors focus on its U.S.-based ISR production ramp-up, with community discussions highlighting its potential to capture rising demand from AI-driven data center power needs. The stock is seeing heavy attention amid a broader nuclear energy narrative, as market participants monitor institutional accumulation and upcoming earnings in anticipation of a potential sector-wide squeeze.

Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. The company was founded by Tadataka Yamada, David Socks, Azmi Nabulsi, Aditya Kohli, and Roger Ulrich on January 9, 2018 and is headquartered in Florham Park, NJ.

Phathom Pharmaceuticals Inc

Phathom Pharmaceuticals is trending as investors monitor institutional accumulation and signs of a potential short squeeze amid anticipation of profitability in the coming quarters. The community is actively discussing the drug's strong prescription growth and its long-term potential as an acquisition target for larger pharmaceutical firms.

Alibaba Group Holding Ltd. engages in providing technology infrastructure and marketing reach. It operates through the following business segments: China Commerce, International Commerce, Local Consumer Services, Cainiao, Cloud, Digital Media and Entertainment, and Innovation Initiatives and Others segments. The Core Commerce segment consists of platforms operating in retail and wholesale. The China Commerce segment includes China commerce retail and wholesale businesses. The International Commerce segment focuses on international commerce retail and wholesale businesses. The Local Consumer Services segment is involved in To-Home businesses, which include Ele.me, local services and delivery platform, and Taoxianda, and To-Destination segment businesses which include Amap, the provider of mobile digital map, navigation and real-time traffic information, and restaurant and local services guide platform. The Cainiao segment has Cainiao Network and offers domestic and international one-stop-shop logistics services and supply chain management solution. The Cloud segment includes Alibaba Cloud and DingTalk. The company was founded by Chung Tsai and Yun Ma on June 28, 1999 and is headquartered in Hangzhou, China.

Alibaba Group Holding Ltd - ADR

Alibaba Group Holding Ltd

Alibaba is generating significant buzz as investors weigh the company's aggressive AI and cloud infrastructure pivot against upcoming earnings and high-stakes geopolitical trade talks. While the community is split between bullish sentiment over long-term AI potential and skepticism surrounding recent earnings volatility, attention is heavily focused on whether institutional positioning will trigger a re-rating for the stock.

Target Corp. engages in the operation and ownership of general merchandise stores. It offers food and general merchandise, clothing and household goods, electronics, and toys. Its brands include A New Day, All in Motion, Art Class, Auden, AVA & VIV, Boots and Barkley, Brightroom, Bullseye's Playground, Casaluna, Cat & Jack, Cloud Island, Colsie, dealworthy, Embark, Everspring, Favorite Day, Figmint, Future Collective, Gigglescape, Good & Gather, Goodfellow & Co, Hearth & Hand with Magnolia, Heyday, Hyde & EEK! Boutique, JoyLab, Kindfull, Kona Sol, Made By Design, Market Pantry, Mondo Llama, More Than Magic, Opalhouse, Open Story, Original Use, Pillowfort, Project 62, Room Essentials, Shade & Shore, Smartly, Smith & Hawken, Sonia Kashuk, Spritz, Sun Squad, Threshold, Universal Thread, up&up, Wild Fable, Wondershop, Xhilaration, California Roots, Casa Cantina, The Collection, Headliner, Jingle & Mingle, Rosé Bae, Photograph, SunPop, and Wine Cube. The company was founded by George Draper Dayton in 1902 and is headquartered in Minneapolis, MN.

Target Corp

Target is drawing significant market attention as a key retail earnings play, with the community actively debating whether the company's recent turnaround initiatives and leadership changes can justify its year-to-date performance. Investors are closely scrutinizing signs of a rebound in comparable sales and the retailer's ability to navigate persistent consumer spending pressures in a competitive big-box environment.

Kraken Robotics, Inc. engages in the design, manufacture, and sale of software-centric sensors, subsea batteries, thrusters and underwater robotic systems. It operates through the following geographical segments: Asia Pacific, Europe, Middle East and Africa, North America, and Other. The company was founded on May 14, 2008, and is headquartered in Mt. Pearl, Canada.

Kraken Robotics Inc

Kraken Robotics is seeing significant community interest driven by its strategic acquisition of Covelya Group, which bolsters its subsea technology platform, and heightened geopolitical focus on critical underwater infrastructure protection. Investors are actively discussing the company's long-term defense sector role, its potential for major exchange uplisting, and strong revenue growth outlook.

Evolution Metals & Technologies Corp. engages in developing a global supply chain for critical minerals and materials. It focuses on automotive, renewable energy, and military and defense sectors. The company is headquartered in West Palm Beach, FL.

Evolution Metals & Technologies Corp.

Evolution Metals & Technologies Corp. Common Stock

Evolution Metals & Technologies is drawing significant investor interest due to its pivot toward a vertically integrated U.S. supply chain for critical minerals and rare earth magnets, which community members view as a strategic hedge against international trade tensions. While some participants are wary of potential volatility and bot activity, the stock is currently trending on the back of news regarding infrastructure expansion and institutional investment, fueling speculation about its long-term role in domestic industrial independence.

Bankr is an advanced AI agent focused on simplifying the process of buying and selling digital assets. Bankr was the first AI agent on Farcaster to help you quickly buy all your favorites coins directly in the social. BankrCoin is the official coin of the agent and was deployed by Bankr itself directly in the Farcaster social feed. Fees from swaps go to support BankrCoin. Bankr is available on Farcaster and will soon be launching a private terminal, token recs, and limit orders on Base.

BankrCoin

BankrCoin is attracting significant attention as investors highlight its role as an AI-powered infrastructure project on the Base ecosystem, with community members actively discussing its long-term potential as an undervalued asset. The sentiment is fueled by consistent development updates from the team and strong ecosystem volume, leading many to hold through market volatility in anticipation of future price appreciation.

Karyopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company was founded by Joseph Araujo, Ronald A. DePinho, Pamela A. Silver, Giulio Draetta, Michael G. Kauffman, and Sharon Shacham on December 22, 2008 and is headquartered in Newton, MA.

Karyopharm Therapeutics Inc

Karyopharm Therapeutics is currently trending due to the completed enrollment of its Phase 3 SENTRY trial for myelofibrosis, though community discussion remains deeply polarized by frustration over persistent financial instability and long-standing concerns regarding executive leadership. Investors are actively debating the potential for a clinical turnaround against the backdrop of an extended cash runway and the company's challenging historical performance.

Stellar is an open-source, decentralized network co-founded in 2014 by Jed McCaleb and Joyce Kim to facilitate the fast and low-cost transfer of value across different currencies and assets globally. Managed by the non-profit Stellar Development Foundation, the project serves as a global infrastructure that connects banks, payment systems, and individuals to expand financial access to underserved populations. Its main value proposition lies in providing a bridge between traditional money and digital networks through the use of Anchors, which are trusted entities that hold deposits and issue credits on the ledger.  The network operates using the Stellar Consensus Protocol and a Federated Byzantine Agreement, where nodes choose trusted sets of other nodes to agree on the state of the ledger. This system ensures high throughput and fast finality, where transactions are considered permanent and irreversible within seconds. Key features include a built-in distributed exchange for trading assets without intermediaries and the Soroban platform for developing smart contracts. Users can also utilize the network for tokenizing real-world assets or accessing decentralized finance services like peer-to-peer lending.  Stellar's native token, XLM, is essential for maintaining network integrity by acting as an intermediary to find efficient exchange paths and preventing spam through small transaction fees and minimum account balance requirements. Unlike many other digital assets, the network has no inflation because the community voted to disable the automatic creation of new tokens. While the project received early funding from the payments company Stripe, it is now sustained by a global community of validators and developers rather than traditional venture capital.

Stellar Lumens

Stellar Lumens is trending as investors debate its potential in the evolving regulatory landscape, specifically surrounding the proposed Clarity Act and its role in real-world asset tokenization. Community sentiment is deeply divided, with some bulls highlighting recent institutional partnerships and network upgrades as long-term catalysts, while vocal bears argue the asset remains underperformant and speculative.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

FDA Clears NVO's Higher Dose of Wegovy: Diversify With These Health ETFs

Novo Nordisk's FDA nod for higher-dose Wegovy could boost healthcare ETFs' appeal, offering diversified exposure to the obesity drug market.

<ul class="summary-bullets"><li>Glenmark launched semaglutide under the brand name GLIPIQ for adults with Type 2 diabetes at ₹325 ($3.5) per week on Saturday.</li><li>The launch comes in a market where GLP-1 drugs such as Ozempic and Mounjaro are available at a much steeper cost.</li><li>The lower price point will reduce the cost barrier for diabetes and weight-loss treatment in India.</li></ul>As demand for diabetes and weight-loss treatments rises, Glenmark Pharmaceuticals Ltd (GLENMARK.NSE) has introduced a cost-effective version of semaglutide in India, aiming to improve affordability in a market dominated by higher-priced alternatives.Glenmark&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://glenmarkpharma.com/gpl_pdfs/media/PR_Glenmark%20Pharmaceuticals%20launches%20GLIPIQ%E2%93%87.pdf">launched</a> semaglutide under the brand name GLIPIQ for adults with Type 2 diabetes on Saturday, with weekly treatment costs starting at ₹325 ($3.5). The drug belongs to a class of medicines that help control blood sugar levels and are also used for weight management.The launch came in the market as GLP-1 drugs like Ozempic and Mounjaro are available at significantly higher prices. Weekly treatment using these can cost around ₹3,000 ($21) or more, depending on dosage and brand. At a more granular level, a 1 mg dose of Ozempic is priced near ₹12,000 ($128), while a 2.5 mg Mounjaro injection costs about ₹3,300 ($35).In comparison, GLIPIQ is priced between ₹325 and ₹440 ($3.5 to $4.7) per week, depending on dosage.Commenting on the launch, Alok Malik, President and Business Head, India Formulations at Glenmark Pharmaceuticals, said, “Affordability is one of the biggest barriers to initiating advanced diabetes treatment in India. With GLIPIQ, we are setting a new benchmark in affordability for GLP-1 drugs, with weekly treatment starting at ₹325.”<a href="https://stocktwits.com/symbol/GLENMARK.NSE/sentiment">GLENMARK.NSE</a> closed at ₹2,180 ($23.19) on Friday, trading up by almost 4%. On Stocktwits, the retail sentiment around GLENMARK.NSE improved from ‘neutral’ to ‘bullish,’ as chatter levels around it remained ‘normal’ over the past day.<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_03_21_at_2_24_01_PM_png_9e2a9418ca.webp" alt="Screenshot 2026-03-21 at 2.24.01 PM.png" width="1160" height="684"><figcaption>StocktwitsGLENMARK.NSE retail sentiment on March 21 as of 2:42 a.m. ET | Source: Stocktwits</figcaption></figure><h2 class="st-heading-2">Global GLP-1 Market</h2>The GLP-1 drug market has been dominated by Novo Nordisk (NVO) and Eli Lilly (LLY), whose products Ozempic and Monjaro are widely used for diabetes and weight management. However, patent expiries have reshaped the landscape.&nbsp;According to a Bloomberg&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2026-03-20/ozempic-copies-to-cost-14-in-india-as-generic-glp-1-era-starts">report</a>, Canada was among the first to lose patent protection for semaglutide earlier this year. The patent for semaglutide is also set to expire this month in China, Brazil, and Turkey. This positioned India as one of the first major markets to see the entry of lower-cost alternatives, as domestic drugmakers began launching competing products at a much lower cost.&nbsp;<h2 class="st-heading-2">How Is Stocktwits Reacting?</h2><stembedurl>https://www.stocktwits.com/TrendonomicsHD/message/648064809</stembedurl>One user on Stocktwits said that Glenmark is showing strong bullish technical signals despite a bearish sentiment. They pointed out that the stock appears to be in a "Stage 2 breakout," meaning it is starting to edge higher.Read also: <a href="https://stocktwits.com/news-articles/markets/cryptocurrency/bitcoin-whale-who-called-crash-warns--debt-hits-wwii/cZ3i55RRIiW">Whale Who Shorted Bitcoin In Black Swan Event Warns As US Debt Hits Highest Since World War II</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Ozempic is medicine for adults with type 2 diabetes that along with diet and exercise may improve blood sugar. While some doctors are prescribing it "off label" for weight loss, on March 17, 2026 in Sydney, Australia. (Photo by Steve Christo/Getty Images)

Glenmark Debuts Budget Semaglutide In India, Undercutting Ozempic By Over 80%

As the patents for semaglutide near expiry in several countries this month, India has introduced a cost-effective alternative.

Equity

As the patents for semaglutide near expiry in several countries this month, India has introduced a cost-effective alternative.


<ul class="summary-bullets"><li>Orforglipron showed greater reductions in A1C blood sugar levels and body weight compared with the oral semaglutide.</li><li>Lilly has filed the drug for approval in more than 40 countries and plans to submit it in the U.S. later this year.</li><li>Eli Lilly is poised to lead the fast-growing GLP-1 market, JPMorgan Chase analyst Chris Schott reportedly said on Wednesday.</li></ul>Eli Lilly and Company (LLY) announced on Thursday that its experimental diabetes pill, Orforglipron, outperformed oral semaglutide in a large Phase 3 study, delivering stronger reductions in blood sugar and greater weight loss over 52 weeks.&nbsp;The 52-week ACHIEVE-3 trial enrolled 1,698 adults with type 2 diabetes and included four treatment groups - Orforglipron at 12 mg and 36 mg doses, and oral semaglutide at 7 mg and 14 mg doses.&nbsp;<a href="https://stocktwits.com/symbol/LLY">LLY shares</a> were up 0.3% in pre-market trading.<h2 class="st-heading-2">Greater Reductions In A1C Blood Sugar Levels And Body Weight</h2>According to Lilly, Orforglipron showed greater reductions in A1C blood sugar levels and body weight compared with the oral semaglutide. The company said that the results were published in The Lancet. This study comes as the oral GLP-1 race intensifies across the sector.Orforglipron delivered meaningful improvements in several key heart health measures, including cholesterol levels, blood pressure, and triglycerides. Its safety profile in the ACHIEVE-3 study was consistent with that observed in earlier trials.The most common side effects for both orforglipron and oral semaglutide were nausea, diarrhea, vomiting, indigestion, and reduced appetite. However, discontinuation rates due to side effects were slightly higher with orforglipron compared to oral semaglutide.Lilly has filed the drug for approval in more than 40 countries and plans to submit it in the U.S. later this year.“The results of ACHIEVE-3 highlight the potential advantages of Orforglipron over oral semaglutide for type 2 diabetes: greater A1C reduction, more weight loss, and the ability to take it without food or water timing restrictions — that’s a combination that could matter significantly to people managing their disease day in and day out,” said Kenneth Custer, Ph.D., executive vice president and president of Lilly Cardiometabolic Health.<h2 class="st-heading-2">Lilly To Lead GLP-1 Market, JPMorgan Says</h2>Eli Lilly is poised to lead the fast-growing GLP-1 market, JPMorgan Chase analyst Chris Schott reportedly said. According to a CNBC article on Wednesday, Schott said Lilly’s “best-in-class” position and its direct-to-consumer platform, LillyDirect, could help it beat expectations as demand for weight-loss drugs rises.Schott estimates that by 2030, about 8 million patients could pay cash for GLP-1 treatments, benefiting Lilly. He also sees further upside when Lilly launches its oral drug. When Medicare begins covering GLP-1s in April, Schott believes Lilly will gain the most, with 4.5 million Medicare patients projected to use the drugs by 2030.Retail sentiment on Stocktwits remained ‘neutral’ over the past 24 hours.Year-to-date, the stock has fallen around 5%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/array-arry-stock-crashes-pre-market-200-dma-q4-results/cZTGfpIRIbu">ARRY Stock Cracks 26%, On Track To Hit 200-DMA For First Time In 3 Months – Retail Says Valuation Is ‘Cheap’</a> For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, an Eli Lilly and Company logo seen displayed on a smartphone. (Photo Illustration by Igor Golovniov/SOPA Images/LightRocket via Getty Images)

Eli Lilly’s Diabetes Pill Outperforms Oral Semaglutide in Phase 3 Trial

Investors are closely watching the oral GLP-1 race as competition intensifies across the sector.

Eli Lilly’s Oral GLP-1 Pill Showed Stronger A1C Drop, Weight Loss Than Oral Semaglutide 

<ul class="summary-bullets"><li>Vivtex will license select drug-delivery technologies to Novo Nordisk and could receive up to $2.1 billion.</li><li>The partnership looks to enable biologic drugs, which are typically given by injection due to poor absorption, to be delivered orally.</li><li>This partnership comes a day after Novo announced plans to cut U.S. prices for Ozempic and Wegovy by up to 50% from 2027.</li></ul>Novo Nordisk (NVO) announced on Wednesday that it has partnered with Vivtex Corp. to develop next-generation oral biologic medicines for obesity, diabetes, and related conditions.Under the agreement, Vivtex will license select oral drug-delivery technologies to Novo Nordisk and could receive up to $2.1 billion in upfront payments, research funding, milestones, and tiered royalties on future sales.“Partnering with Novo Nordisk allows us to apply our platform across important metabolic disease areas, with the goal of enabling oral therapies that would otherwise require injection,” said Thomas von Erlach, CEO and co-founder of Vivtex.<a href="https://stocktwits.com/symbol/NVO">NVO shares</a> were down 1.8% at the time of writing.<h2 class="st-heading-2">Focus On Oral Delivery</h2>The partnership combines Novo’s expertise in peptide and protein therapies with Vivtex’s gastrointestinal screening tools, drug-delivery technologies, and AI-based platform aimed at improving drug absorption.The collaboration aims to enable biologic drugs, which are typically given by injection due to poor absorption, to be delivered orally. Novo Nordisk will lead global development, regulatory approval, manufacturing, and commercialization of any resulting products, it said.Oral obesity pills are seen as a key focus area in the obesity market, eliminating the need for injections and giving patients greater flexibility.This comes a day after Novo Nordisk <a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-cut-ozempic-wegovy-prices-by-50/cZRvxJeR4C2">announced</a> plans to cut U.S. prices for Ozempic and Wegovy by up to 50% starting in 2027.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits remained in the ‘extremely bullish’ zone over the past 24 hours, amid ‘extremely high’ message volumes.One user sees the stock as a “short-term buy” option.<stembedurl>https://stocktwits.com/buddyopalosam/message/645859049</stembedurl>Another user said the stock was ‘undervalued.’<stembedurl>https://stocktwits.com/Matt_Y_/message/645842315</stembedurl>Year-to-date, the stock is down around 27%.For updates and corrections, email newsroom[at]stocktwits[dot]com.&nbsp;

In this photo illustration, the logo of Novo Nordisk is displayed on a smartphone screen on September 10, 2025 in Chongqing, China. 

Novo, Vivtex Ink $2.1 Billion Deal To Develop Oral Medicines For Obesity And Diabetes

Novo Nordisk will lead global development, regulatory approval, manufacturing, and commercialization of the resulting products.

<ul class="summary-bullets"><li>The Danish pharmaceutical giant is expanding operations at its Athlone site.</li><li>CEO Mike Doustdar did not disclose how much the company plans to spend.</li><li>&nbsp;Doustdar said more than 240,000 people in the U.S. have already begun taking Wegovy in the form of pills.</li></ul>Novo Nordisk (NVO) is reportedly planning to ramp up its manufacturing footprint in Ireland as it prepares to increase production of its blockbuster Wegovy weight-loss pill for patients outside the U.S.&nbsp;According to a Bloomberg&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2026-02-12/novo-set-to-make-wegovy-pill-in-ireland-for-markets-outside-us?srnd=homepage-americas">report</a>, Novo’s CEO, Mike Doustdar, said the company will expand its facility in Ireland’s midlands region to support international demand for the oral version of Wegovy.Doustdar did not disclose how much the company plans to spend but emphasized that the expansion signals confidence in the product’s global prospects. The Danish pharmaceutical giant is expanding operations at its site in Athlone, a move that underscores its renewed push in the highly competitive obesity drug market.<a href="https://stocktwits.com/symbol/NVO">Novo Nordisk stock</a> inched 0.6% higher in Thursday’s premarket. On Stocktwits, retail sentiment around the stock remained in ‘bearish’ territory while message volume shifted to ‘normal’ from ‘high’ levels in 24 hours.&nbsp;<h2 class="st-heading-2">Strong Early Demand</h2>The report cited that Wegovy’s pill form debuted in early January and quickly gained traction. Doustdar said more than 240,000 people in the U.S. have already begun taking the medication, calling it one of the most successful rollouts in the industry.Novo manufactures the U.S. supply domestically, while the Irish site will focus on serving markets beyond the U.S. On Wednesday, Doustdar said the company is planning to offer Wegovy injectables in vial form, similar to what competitor Eli Lilly and Company (LLY) has done.The latest push in Ireland comes as Novo works to regain momentum in the weight-management segment it once led. The company had previously warned about several challenges in 2026, including intense competition, lower selling prices, and the loss of patent protection for the main ingredient in its drugs, Wegovy and Ozempic, in some countries outside the U.S.NVO stock has declined by over 40% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/rivian-stock-rises-premarket-ahead-of-q4-earnings-r2-suv-reveal-nears-benchmark-sees-upside/cZRThmWR4AC">Rivian Stock Rises Premarket Ahead Of Q4 Earnings As R2 SUV Reveal Nears — Benchmark Sees Over 20% Upside</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

The Novo Nordisk logo is seen with tablets, capsules, and syringes in this photo illustration in Brussels, Belgium, on August 9, 2025. 

Novo Looks To Ireland To Scale Production Of Wegovy Pill: Report 

According to a Bloomberg report, Novo’s CEO, Mike Doustdar, said the company will expand its facility in Ireland’s midlands region to support international demand for the oral version of Wegovy.

<ul class="summary-bullets"><li>GDNF outperformed semaglutide, the active ingredient in Wegovy and Ozempic, across several key measures, Hoth said.</li><li>The 12-week study showed that female mice on a high-fat diet experienced a 10% to 15% reduction in weight gain with GDNF, whereas semaglutide showed no meaningful effect.</li><li>The company said GDNF reduced liver weight by 20% to 30% and prevented fat buildup, highlighting its potential to address fatty liver disease.</li></ul>Hoth Therapeutics (HOTH), on Tuesday, announced preclinical results from a Veterans Administration-backed study evaluating glial cell-derived neurotrophic factor (GDNF) as a potential treatment for obesity and metabolic-associated steatotic liver disease (MASLD).The company stated that in a head-to-head comparison, GDNF outperformed semaglutide, the active ingredient in weight-loss drugs such as Wegovy and Ozempic, across several key measures, including weight control, glucose tolerance, liver weight reduction, and adipose tissue control.<a href="https://stocktwits.com/symbol/HOTH">HOTH shares</a> were up over 5% in pre-market trading but reversed gains after the opening bell, trading 6% lower.<h2 class="st-heading-2">What Did The 12-Week Study Show?</h2>During the 12-week study, female mice on a high-fat diet experienced a 10% to 15% reduction in weight gain with GDNF, eventually entering a stabilization phase, whereas semaglutide showed no meaningful effect. Researchers noted that higher doses or longer durations could amplify GDNF’s effects.GDNF also normalized fasting glucose levels and improved responses to glucose challenges. Additionally, the therapy reduced liver weight by 20% to 30% and prevented fat buildup, highlighting its potential to address fatty liver disease, a common issue with obesity.“These results are a monumental step forward for Hoth and the fight against obesity. GDNF not only matched but exceeded semaglutide in critical areas, opening doors to a new era of safer, more effective therapies,” said Robb Knie, CEO of Hoth Therapeutics.<h2 class="st-heading-2">What’s Next?</h2>Hoth plans additional studies on liver pathology, lipid content, and gene and protein expression to better understand GDNF’s mechanism, with clinical trials targeted for 2027.Weight-loss drugs have become a central focus for the pharmaceutical industry, driving revenue growth for leaders like Eli Lilly and Novo Nordisk as other companies race to enter the booming market.The segment has been under regulatory spotlight in the aftermath of Hims &amp; Hers launching a compounded version of Wegovy last week, which the company has since withdrawn following legal notices from NOVO and the U.S. Food and Drug Administration.&nbsp;&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment turned ‘bullish’ from ‘neutral’ a day earlier, accompanied by ‘high’ message volumes.<img src="https://news.stocktwits-cdn.com/HOTH_jpg_40deb046fb.webp" alt="HOTH.jpg">One user called for patience amid the intraday decline.<stembedurl>https://stocktwits.com/Tom678/message/644546402</stembedurl>HOTH shares are down around 21% so far this year.Read also: <a href="https://stocktwits.com/news-articles/equity/markets/why-did-azi-stock-reverse-gains-in-premarket/cZbUIHFR4Yy">AZI Stock Reverses Early Gains To Slump 30% In Pre-Market – What Happened?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

06 February 2025, Baden-Württemberg, Rottweil: A candlestick chart is opened in a trading platform on a smartphone. Photo: Silas Stein/dpa

Hoth Therapeutics' GDNF Treatment Shows Superior Efficacy Over Wegovy, Ozempic In Preclinical Trial

The company announced positive preclinical results from a study evaluating GDNF as a potential treatment for obesity and metabolic-associated steatotic liver disease.

<ul class="summary-bullets"><li>Hims &amp; Hers said the compounded copy uses the same active ingredient as Wegovy but features a different formulation and delivery system.</li><li>The compounded pill will start at the introductory pricing for the first month for qualifying new customers under a five-month plan.</li><li>The pill is engineered to preserve the active ingredient during digestion and improve absorption.</li></ul>Shares of Hims &amp; Hers Health, Inc. (HIMS) rose 10% on Thursday after the company announced the launch of a compounded copy of the Wegovy weight-loss pill at an introductory price of $49 per month.Hims &amp; Hers said the compounded copy uses the same active ingredient as Wegovy but features a different formulation and delivery system from the FDA-approved oral semaglutide. Novo Nordisk originally introduced Wegovy as a once-weekly injection and expanded the franchise earlier this year with the launch of an oral pill version.<h2 class="st-heading-2">$100 Cheaper Than Novo’s Wegovy</h2>Hims &amp; Hers said treatment plans using the compounded pill will start at an introductory $49 for the first month for qualifying new customers under a five-month plan. The remaining months are priced at $99 per month, payable in advance.According to Novo Nordisk’s website, Wegovy pills are priced at $149 per month for a 1.5 mg dose.Hims &amp; Hers stated that its compounded pill is engineered to preserve the active ingredient during digestion and improve absorption, offering an alternative for patients who want to avoid injections.Meanwhile, NVO shares fell nearly 6%.<h2 class="st-heading-2">Novo’s Pricing Challenges</h2>Earlier this week, Novo said it expects adjusted sales for full year 2026 to drop between 5% and 13%, with operating profit potentially falling by 13% due to pricing pressure, intensifying competition, and upcoming patent expiries for key ingredients in Wegovy and Ozempic in select markets outside the U.S.“Our 2026 guidance reflects a year of unprecedented pricing pressure,” CEO Mike Doustdar said in a call with journalists on Wednesday. Doustdar added that Novo would have to accept short-term pain to lift volumes, arguing that lowering prices would pay off in the long-run.The pill variant has already seen significant traction since its launch in January.“I can tell you, as of this week, we have over 170,000 people that are on the Wegovy pill, and most of that is self-pay,” Doustdar said in a call with analysts.Eli Lilly (LLY), the maker of weight-loss drugs Mounjaro and Zepbound, saw its shares fall 6.5%.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/HIMS">HIMS</a> on Stocktwits turned ‘extremely bullish’ from ‘bullish’ a day earlier, while chatter was ‘extremely high’ on the platform.One user saw the new launch as a “trend changing event.”<stembedurl>https://stocktwits.com/Dr_Stoxx/message/644091407</stembedurl>Another bullish user highlighted HIM’s latest developments.<stembedurl>https://stocktwits.com/tothebulltothewall/message/644092695</stembedurl>Year-to-date, the stock has declined around 20%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-b-stock-is-falling-despite-q4-beat/cZbZB3uR4VV">Barrick’s Q4 Earnings Beat Expectations – So, What Is Dragging The Stock Down In Premarket Today?</a> For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a smartphone displays the logo of Hims & Hers Health in front of a screen showing the company's stock market chart. (Photo illustration by Cheng Xin/Getty Images)

HIMS New $49 Pill Lifts Stock 10%, But Why Are NVO, LLY Stocks Falling?

The company announced the launch of a compounded copy of the Wegovy weight-loss pill at an introductory price of $49 per month.

HIMS Stock Rises On Low-Cost Wegovy Alternative, Raising New Pricing Questions For Novo And Lilly

The company announced the launch of a compounded copy of the Wegovy weight-loss pill at an introductory price of $49 per month.



Healthcare ETFs to Watch as Novo Nordisk Tumbles on Poor Sales Outlook

Novo Nordisk slides 15% on a cautious 2026 sales outlook, but buybacks, leadership moves and Wegovy expansion put its ETFs in focus.

<ul class="summary-bullets"><li>In an interview with CNBC on Wednesday, CEO Doustdar said people should expect the company’s share price to go down before it goes back up.</li><li>NVO shares fell 4.5% in pre-market trading on Wednesday, extending Tuesday’s losses after the drugmaker issued a weak outlook for fiscal 2026.</li><li>Novo attributed the outlook to pricing pressure, and rising competition.</li></ul>Novo Nordisk (NVO) expects the U.S. Food and Drug Administration to decide on a higher-dose version of its Wegovy weight-loss drug in the first quarter of fiscal 2026.“Novo Nordisk submitted the high-dose semaglutide 7.2mg to the FDA in November. It’s under the CNPV pilot program, and we anticipate a decision during the first quarter of 2026,” Novo’s CEO Mike Doustdar said in a call with analysts on Wednesday.Novo Nordisk submitted a supplemental New Drug Application (NDA) to the FDA in November, and under the Commissioner’s National Priority Voucher expedited program, a review decision is usually expected within one to two months after the filing is accepted.<a href="https://stocktwits.com/symbol/NVO">NVO shares</a> were down 4.5% in pre-market trading on Wednesday.<h2 class="st-heading-2">Weak 2026 Outlook Weighs On Shares&nbsp;</h2>The stock extended Tuesday’s losses of over 14% after the drugmaker issued a soft outlook for fiscal 2026, warning that sales and profit growth could decline amid mounting industry pressures. The company expects adjusted sales to fall between 5% and 13%, and operating profit could decline by up to 13%.Novo attributed the outlook to pricing pressure, rising competition, and upcoming patent expiries for the active ingredients in blockbuster drugs Wegovy and Ozempic in certain markets outside the U.S.In an interview with CNBC on Wednesday, Doustdar said people should expect the company’s share price to go down “before it comes back up.”The cautious forecast follows a disappointing 2025 performance. Novo reported net sales of DKK 309.06 billion ($48.9 billion), up 6% year over year but well below analyst estimates of DKK 346.97 billion.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Despite the intraday decline, retail sentiment on Stocktwits turned ‘bullish’ from ‘bearish’ a day earlier, amid ‘extremely high’ message volumes.<figure class="image"><img src="https://news.stocktwits-cdn.com/NVO_jpg_0be70277b2.webp" alt="NVO.jpg" width="931" height="105"><figcaption>NVO's Sentiment Meter and Message Volumes at Premarket on Feb. 4, 2026 | Source: Stocktwits</figcaption></figure>One user said that the bearish guidance was a “self-inflicted wound.”<stembedurl>https://stocktwits.com/DJEuphoria/message/643918854</stembedurl>However, another user highlighted Novo’s strong grip in the diabetes and obesity markets.<stembedurl>https://stocktwits.com/Valconomics/message/643892305</stembedurl>NVO shares have plummeted around 40% over the past year.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/eli-lilly-lly-stock-jumps-fy26-guidance-zepbound-mounjaro/cZbSCjgR4Zl">LLY Stock Surges Pre-Market: Obesity, Diabetes Drugs Drive Strong FY26 Outlook</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Novo Awaits FDA Call On Higher-Dose Wegovy In Early 2026 – NVO Stock Extends Decline Pre-Market On Weak Guidance

Novo Nordisk submitted a supplemental New Drug Application (NDA) to the FDA in November, and under the CNPV program, a review decision is usually expected within one to two months after the filing is accepted.

Novo Awaits FDA Call On Higher-Dose Wegovy In Early 2026 – NVO Stock Extends Decline Pre- Market On Weak Guidance

<ul class="summary-bullets"><li>Eli Lilly issued a revenue guidance between $80 billion and $83 billion for fiscal 2026</li><li>For the full year 2025, Eli Lilly’s revenue grew 45% to $65.18 billion.</li><li>CFO Lucas Montarce said the company expects to launch the multidose Zepbound within the next 30 days, according to a Bloomberg report.</li></ul>Shares of Eli Lilly (LLY) jumped 8% in pre-market trading on Wednesday, after the company reported better-than-expected fourth-quarter results and issued a revenue guidance between $80 billion and $83 billion for fiscal 2026, significantly above fiscal 2025 revenue.<a href="https://stocktwits.com/symbol/LLY">LLY shares</a> were up 9.2% after the opening bell.Fourth-quarter revenue surged 43% to $19.3 billion, driven by volume growth from Mounjaro and Zepbound – signalling sustained momentum in its obesity and diabetes portfolio. Analysts had expected a revenue of $17.86 billion, according to Fiscal.ai data. Meanwhile, Q4 earnings increased by 51% to $7.39 per share on a reported basis, compared to Street estimates of $7.22 per share.For the full year, Eli Lilly’s revenue grew 45% to $65.18 billion. LLY expects earnings of $33.50 to $35 per share for full-year 2026.<h2 class="st-heading-2">Mounjaro And Zepbound Drive Revenue Growth</h2>Global revenue for Mounjaro surged 110% to $7.4 billion in Q4 2025, with U.S. sales rising 57% to $4.1 billion on strong demand despite lower realized prices. International revenue jumped to $3.3 billion from $899 million a year earlier, driven mainly by volume growth.U.S. Zepbound revenue climbed 122% to $4.2 billion, fueled by higher demand but partially offset by pricing pressure. Meanwhile, revenue from Verzenio, Eli Lilly’s drug to treat metastatic breast cancer, edged up 3% to $1.6 billion.<h2 class="st-heading-2">Eli Lilly’s Product Pipeline</h2>After the FDA authorized Lilly to market Zepbound in a multidose device last month, CFO Lucas Montarce said the company expects to launch the multidose pen within the next 30 days, according to a report by Bloomberg on Wednesday.In an interview with CNBC last month, CEO Dave Ricks said the upcoming Medicare coverage for obesity drugs could significantly boost the launch of its experimental weight-loss pill, Orforglipron. Ricks added that the company expects Medicare coverage to begin immediately after the drug’s launch.<h2 class="st-heading-2">LLY Pulls Ahead As NOVO Faces Headwinds</h2>Eli Lilly’s optimistic outlook stands in stark contrast to Novo Nordisk (NVO), which expects adjusted sales to decline between 5% and 13% and operating profit to drop by up to 13%. The company cited pricing pressure, intensifying competition, and upcoming patent expiries for the key ingredients in Wegovy and Ozempic in select markets outside the U.S.“This is just more evidence they are dominating the category,” Mizuho’s Jared Holz told Bloomberg of Eli Lilly’s obesity market position. “Novo is playing from behind and everyone knows it.”<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits turned ‘bullish’ from ‘bearish’ over the past 24 hours, amid ‘high’ message volumes.<figure class="image"><img src="https://news.stocktwits-cdn.com/LLY_jpg_1dcca688cf.webp" alt="LLY.jpg" width="933" height="102"><figcaption>LLY's Sentiment Meter and Message Volumes on Feb. 4, 2026 | Source: Stocktwits</figcaption></figure>One user said that Lilly proved that with “a good product comes great demand.”<stembedurl>https://stocktwits.com/Bagholding_VKTX/message/643931351</stembedurl>LLY shares have gained around 25% over the past year.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-fda-higher-dose-wegovy-nvo-stock-outlook/cZbjThlR4ZM">Novo Awaits FDA Call On Higher-Dose Wegovy In Early 2026 – NVO Stock Extends Decline Pre-Market On Weak Guidance</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

LLY Stock Surges On Q4  Beat – Obesity, Diabetes Drugs Drive Strong FY26 Outlook

LLY Stock - Fourth-quarter revenue surged 43% to $19.3 billion, above Street estimates of $17.86 billion, according to Fiscal.ai data.

Fourth-quarter revenue surged 43% to $19.3 billion, above Street estimates of $17.86 billion, according to Fiscal.ai data.

OZEM
Roundhill GLP-1 & Weight Loss ETF

Feed

News

Sentiment

Fundamentals

Info

Compact View

Latest OZEM News

OZEMRoundhill GLP-1 & Weight Loss ETF